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Exploiting new uses for old drugs has important implications for development of 
anti-cancer drugs. Some successful examples for this type of cancer drug development 
were previously reported such as thalidomide, vitamin C, NSAIDs (nonsteroidal 
anti-inflammatory drugs). It has been demonstrated that artemisinin, an antiparasitic 
agent, and its derivatives, had profound anti-tumor activity, providing the impetus to 
develop antiparasitic drugs for cancer prevention and treatment. Praziquantel (PZQ), 
another anti-schistosome agent, has been widely used for treatment of all forms of 
schistosomiasis with high efficacy and excellent tolerability. However, it is unclear 
whether PZQ also has anti-cancer effect. In this study, we showed that PZQ could 
greatly enhance paclitaxel (PTX)-induced cell growth inhibition in various tumor cell 
lines, including PTX-resistant cell lines, although PZQ treatment alone did not affect 
cell viability. A xenograft model in nude mice was established to examine the in vivo 
effects of the PZQ and PTX combination, and we found that this combination 
significantly inhibited tumor growth in vivo in comparison with either PZQ or PTX 
treatment alone. The Calcusyn analysis indicated that PZQ interacted in a highly 
synergistic way with PTX to inhibit cell viability. In addition, the synergism between 
PZQ and PTX seemed to be independent of p53, as it was observed in tumor cells 
with different p53 status, and knockdown of p53 in cells expressing wild-type p53 did 
not affect cell sensitivity to the co-treatment of PZQ and PTX. Combined treatment 
with PZQ and PTX also resulted in a marked increase in apoptosis induction 
compared with either agent treatment alone. Further analysis showed that the 
sensitization of PTX-mediated cell apoptosis by PZQ depended on caspase activity.  
Cell cycle analysis showed that the co-treatment of PZQ and PTX dose-dependently 
increased the G2/M population compared with PTX treament alone. We subquently 
clarify the profile of G2/M-accumulated cells by analysis of mitotic index, and found 
that PZQ could enhance PTX-induced mitotic arrest in tumor cells. We then examined 
whether there was a correlation between mitotic arrest and apoptosis induced by this 















PZQ and PTX likely resulted from increased mitotic arrest induced by this 
co-treatment. To evaluate the underlying mechanism of synergistic cytotoxicity by 
PZQ and PTX, we assessed the effects of the two agents, either alone or in 
combination, on various apoptosis and signaling regulatory proteins. Exposure of cells 
to both PZQ and PTX together could markedly down-regulate expression of XIAP 
and phospho-ERK1/2. We found further that down-regulation of XIAP and 
phospho-ERK1/2 was required for the synergistic interaction between PZQ and PTX. 
Taken together, we showed the anti-cancer potential of PZQ, which exerted 
synergistic cytotoxicity while combined with PTX. Considering enormous challenges 
for PTX therapy because of the emergence of clinical resistance and severe side 
effects, the co-treatment of PZQ and PTX may provide a useful strategy for these 
challenges and has important implications for PTX-based therapy. Moreover, because 
PZQ is a clinically used drug, our findings may be readily translated to clinical 
practice. 
From another perspective of novel anti-cancer drug development, this thesis also 
describes an assay for screening spindle checkpoint inhibitors. In eukaryotes, the 
spindle checkpoint acts as a surveillance mechanism that ensures faithful chromosome 
segregation. The spindle checkpoint prevents premature separation of sister 
chromatids and the onset of anaphase until every chromosome is properly attached to 
the mitotic spindle. Tumorigenesis might result from generation of aneuploidy by 
dysfunction of the spindle checkpoint. Difference of the checkpoint system in normal 
cells versus tumor cells might provide a new opportunity in cancer drug development, 
therefore effort to identify the spindle checkpoint inhibitors has been fostered. Based 
on the fact that spindle checkpoint inhibitors are able to induce cells to exit from 
mitotic arrest caused by microtubule drug treatment, we developed a cell-based assay 
to screen compounds of the spindle checkpoint inhibitors (The paper was published in 
ASSAY and Drug Development Technologies, 2012). This assay was validated with a 
known spindle checkpoint inhibitor, and was easy to adapt to a large-scale screening 
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维生素 C 有细胞毒效应[5]，而且维生素 C 可提高 epirubicin、5-Fu 等多种化疗药





























































在对青蒿素敏感的细胞中青蒿素能下调 β-catenin 的表达，并诱导 E-cadherin 的















正常小鼠的 20%，当给 B 细胞缺陷的小鼠注射正常的抗血清后，吡喹酮对血吸
虫的治疗率有显著提高，进一步发现，在经吡喹酮治疗后的正常小鼠中分离得到




到 T 调节细胞的水平下降，表明吡喹酮可以影响 T 调节细胞[22]。近年来还发现，
吡喹酮作为一种辅助剂，可促进 T 细胞增殖，并提高小鼠对 HBSAg DNA 疫苗
的免疫反应。进一步的研究发现，HBSAg 可以诱导 TGF-β的表达，而吡喹酮能
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